Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY12 | Q9H244 | 18/20 | 0.81 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.61 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.59 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.59 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.59 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13614733 | 1.00 | P2RY12 (0.81) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13621909 | 0.94 | P2RY12 (0.89) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13632551 | 0.94 | P2RY12 (0.89) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13621905 | 0.94 | P2RY12 (0.89) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13632552 | 0.94 | P2RY12 (0.89) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL14531305 | 0.94 | P2RY12 (0.89) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13614696 | 0.93 | P2RY12 (0.81) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13614698 | 0.93 | P2RY12 (0.81) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13614708 | 0.93 | P2RY12 (0.78) | P2RY12P2RY2P2RX3P2RX4P2RX7 | |
| SCHEMBL13614706 | 0.93 | P2RY12 (0.78) | P2RY12P2RY2P2RX3P2RX4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612047-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | disclosed |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | DOUGLASS III JAMES G | 2009-03-19 | — | — | US | disclosed |
| US-7435724-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICAL, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-7435724-B2 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICAL, INC. (US) | 2008-10-14 | — | — | US | disclosed |
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | INSPIRE PHARMACEUTICALS, INC. | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244068-A1 | Degradation-resistant mononucleoside phosphate compounds | PNKP, ENTPD5, ENPP1 | P2RY12 65/4885P2RY2 75/4885P2RX3 143/4885 |
| US-20090076256-A1 | DEGRADATION-RESISTANT MONONUCLEOSIDE PHOSPHATE COMPOUNDS | PNKP, ENTPD5, ENPP1 | P2RY12 65/4885P2RY2 75/4885P2RX3 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.